Confluence's mission is to advance all research in Autism and Fragile X Syndrome and bring to market a solution that treats core social and communication impairments. We understand the profound impact of being able to communicate and socially interact has on everyday life.
Confluence is developing a novel, clinically-discovered therapeutic treatment for core social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders.We are targeting important functionality - talking, thinking, social interaction, and self-care.
Confluence is developing a novel, clinically-discovered therapeutic treatment for core social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders.We are targeting important functionality - talking, thinking, social interaction, and self-care.
Services
Confluence has assembled an experienced management team, Business and Science Advisory Boards, and attracted various other important collaborators to our effort. The management team's experience spans from the launch of new businesses, through capitalization, commercialization and exit.
Steve Johns has built a reputation as a Visionary Innovator and Leader through a variety of diverse experiences acquired in a number of successful start-ups and early stage companies.His work career includes 10 years in Banking / Financial Management and 15 years in his own business ventures.
Steve Johns has built a reputation as a Visionary Innovator and Leader through a variety of diverse experiences acquired in a number of successful start-ups and early stage companies.His work career includes 10 years in Banking / Financial Management and 15 years in his own business ventures.
Reviews
Be the first to review Confluence Pharmaceuticals.
Write a Review
